

Supplementary Document V – benchmark study including clinical parameters reported

| <i>Study</i> | <i>Treatment [N]</i> | <i>Parameters</i> | | <i>Outcome</i> | <i>Value</i> | <i>Model</i> |
|--------------|----------------------|-------------------|-----|----------------|--------------|--------------|
| Hamdy 2016 | EBRT [545] | Age (years) | 62 | 5 year BDFS | 88.5% | 89.0% |
| | | GS 7 | 21% | | | |
| | | T2 | 25% | | | |
| | | PSA <10 | 90% | | | |
| | | PSA ng/ml | 4.7 | | | |
| | RP [553] | Age (years) | 62 | 5 year BDFS | 88.1% | 87.0% |
| | | GS 7 | 21% | | | |
| | | T2 | 25% | | | |
| | | PSA <10 | 90% | | | |
| | | PSA ng/ml | 4.7 | | | |
| CHHiP | 74 Gy [1065] | Age (years) | 69 | 5 year BDFS | 88.5% | 88.4% |
| | | T2 | 58% | | | |
| | | GS 7 | 64% | | | |
| | | ADT | 83% | | | |
| | | ADT months | 6.2 | | | |
| | 60 Gy [1074] | Age (years) | 69 | 5 year BDFS | 91.3% | 89.9% |
| | | T2 | 58% | | | |
| | | GS 7 | 63% | | | |
| | | ADT | 85% | | | |
| | | ADT months | 6.2 | | | |
| | 57 Gy [1077] | Age (years) | 69 | 5 year BDFS | 86.8% | 87.9% |
| | | T2 | 58% | | | |
| | | GS 7 | 65% | | | |
| | | ADT | 84% | | | |
| | | ADT months | 6.2 | | | |
| Donovan 2016 | EBRT [545] | Age (years) | 62 | 6 month UI | 5% | 3.3% |
| | | GS 7 | 20% | 6 year UI | 3.5% | 3.3% |
| | | T2 | 21% | 6 month ED | 77.8% | 85.4% |
| | | PSA (ng/ml) | 4.8 | 6 year ED | 72.6% | 71.6% |
| | | | | 6 month RB | 3.8% | 14.7% |
| | | | | 6 year RB | 5.6% | 5.7% |
| | RP [553] | Age (years) | 62 | 6 month UI | 46% | 41.5% |
| | | GS 7 | 22% | 6 year UI | 17% | 17.0% |
| | | T2 | 26% | 6 month ED | 88% | 92.7% |
| | | PSA (ng/ml) | 4.9 | 6 year ED | 83.5% | 83.7% |
| | | | | | | |
| | | | | | | |

N: number of patients; EBRT: external beam radiotherapy; RP: radical prostatectomy; BDFS: biological disease free survival; UI: urinary incontinence; ED: erectile dysfunction; RB: rectal bleeding; Gy: gray; GS: gleason score; PSA: prostate specific antigen in ng/ml; ADT: androgen deprivation therapy